The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice
Oestrogen receptor positive early invasive breast cancer is a common disease in pre- and perimenopau...
Although the survival of breast cancer has improved the past decades, there is still major over- and...
Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expre...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant e...
RATIONALE: Patients with, or who develop, metastatic breast cancer have a 5-year relative survival o...
Purpose: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immuno...
Since the initial studies of adjuvant therapy in the 1970s, it has become increasingly clear that ch...
Background: Chemotherapy, tamoxifen and ovarian function suppression have all demonstrated their eff...
Approximately three quarters of all invasive breast tumors are estrogen or progesterone receptor–pos...
Cytoreductive surgery is the mainstay of treatment for high-grade epithelial ovarian cancer. Althoug...
This thesis describes several important aspects of adjuvant endocrine therapy for postmenopausal wom...
Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive t...
Purpose: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immuno...
BACKGROUND: Hormone receptor-positive advanced breast cancer is an increasing health burden. Althou...
Oestrogen receptor positive early invasive breast cancer is a common disease in pre- and perimenopau...
Although the survival of breast cancer has improved the past decades, there is still major over- and...
Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expre...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant e...
RATIONALE: Patients with, or who develop, metastatic breast cancer have a 5-year relative survival o...
Purpose: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immuno...
Since the initial studies of adjuvant therapy in the 1970s, it has become increasingly clear that ch...
Background: Chemotherapy, tamoxifen and ovarian function suppression have all demonstrated their eff...
Approximately three quarters of all invasive breast tumors are estrogen or progesterone receptor–pos...
Cytoreductive surgery is the mainstay of treatment for high-grade epithelial ovarian cancer. Althoug...
This thesis describes several important aspects of adjuvant endocrine therapy for postmenopausal wom...
Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive t...
Purpose: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immuno...
BACKGROUND: Hormone receptor-positive advanced breast cancer is an increasing health burden. Althou...
Oestrogen receptor positive early invasive breast cancer is a common disease in pre- and perimenopau...
Although the survival of breast cancer has improved the past decades, there is still major over- and...
Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expre...